EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BRAF Mutations in Patients with Myeloid Neoplasms: A Cancer Center Multigene Next-Generation Sequencing Analysis Experience

Fei Fei, Caitlin Caporale iD, Lisa Chang, Barbara K Fortini iD, Haris Ali, Diana Bell, Anthony Stein, Guido Marcucci, Milhan Telatar, Michelle Afkhami iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25105183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Fei Fei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Hauptthemen laut MEDLINE: High-Throughput Nucleotide Sequencing, Leukemia, Myeloid, Acute, Mutation, Proto-Oncogene Proteins B-raf. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRAF mutations are rare in myeloid neoplasms and are reported to be associated with poor treatment outcomes. The purpose of our study is to characterize BRAF mutations in myeloid neoplasms using a next-generation sequencing (NGS) panel based on the experiences of a single cancer center. We conducted a retrospective review of patients with myeloid neoplasms who underwent the HopeSeq studies between January 2018 and September 2023. A total of 14 patients with myeloid neoplasms carrying BRAF mutations were included in our cohort. The clinical, pathological, and molecular features of these patients were investigated. Our study indicates that BRAF mutations are rare in myeloid neoplasms, constituting only 0.53% (14/2632) of all myeloid neoplasm cases, with the most common BRAF mutation being BRAF V600E (4/14; 28.6%). Interestingly, we observed that six out of seven patients with acute myeloid leukemia (AML) exhibited AML with monocytic differentiation, and all the patients with AML exhibited an extremely poor prognosis compared to those without BRAF mutations. TET2 (5/14; 35.7%), ASXL1 (4/14; 28.6%), and JAK2 (4/14; 28.6%) were the three most frequently co-mutated genes in these patients. Moreover, we noted concurrent KMT2A gene rearrangement with BRAF mutations in three patients with AML (3/7; 42.9%). Our study suggests that although BRAF mutations are rare in myeloid neoplasms, they play a crucial role in the pathogenesis of specific AML subtypes. Furthermore, RAS pathway alterations, including BRAF mutations, are associated with KMT2A gene rearrangement in AML. However, these findings warrant further validation in larger studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

High-Throughput Nucleotide SequencingLeukemia, Myeloid, AcuteMutationProto-Oncogene Proteins B-rafAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedDioxygenasesDNA-Binding ProteinsJanus Kinase 2PrognosisProto-Oncogene ProteinsRepressor ProteinsRetrospective Studies

Stichwörter der Autor:innen

BRAF mutationmyeloid neoplasmsnext-generation sequencing

Substanzen

ASXL1 protein, humanBRAF protein, humanDioxygenasesDNA-Binding ProteinsJAK2 protein, humanJanus Kinase 2Proto-Oncogene ProteinsProto-Oncogene Proteins B-rafRepressor ProteinsTET2 protein, human

Autor:innen und Institutionen

  • Department of Pathology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
  • Breast Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • Keck Graduate Institute, Claremont, CA 91711, USA.
  • Department of Hematology & Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
  • Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.

ORCID-Profile: Caitlin Caporale, Barbara K Fortini, Michelle Afkhami

Zitieren

APA

Fei, F., Caporale, C., Chang, L., Fortini, B. K., Ali, H., Bell, D., Stein, A., Marcucci, G., Telatar, M., & Afkhami, M. (2024). BRAF Mutations in Patients with Myeloid Neoplasms: A Cancer Center Multigene Next-Generation Sequencing Analysis Experience. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25105183

Vancouver

Fei F, Caporale C, Chang L, Fortini BK, Ali H, Bell D, et al. BRAF Mutations in Patients with Myeloid Neoplasms: A Cancer Center Multigene Next-Generation Sequencing Analysis Experience. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25105183

BibTeX
@article{Fei2024,
  author = {Fei, Fei and Caporale, Caitlin and Chang, Lisa and Fortini, Barbara K and Ali, Haris and Bell, Diana and Stein, Anthony and Marcucci, Guido and Telatar, Milhan and Afkhami, Michelle},
  title = {BRAF Mutations in Patients with Myeloid Neoplasms: A Cancer Center Multigene Next-Generation Sequencing Analysis Experience},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25105183}
}
Kostenlos starten →